Overview: SMN1 Exon 8 TestIntroduction: The SMN1 Exon 8 Test tests for SMN1 exon 8 deletions to diagnose spinal muscular atrophy, causing muscle weakness, aiding in genetic diagnosis and treatment. Affecting 1 in 10,000 newborns, spinal muscular atrophy poses diagnostic challenges due to early onset. Following 2023 Muscular Dystrophy Association (MDA) guidelines, it uses PCR for high accuracy, supporting molecular pathology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in neurology.
Other Names: SMN1 Exon 8 Deletion Test, SMA Gene Assay.
FDA Status: FDA-approved test, meeting pathology standards for diagnostic reliability.
Historical Milestone: SMN1 exon 8 testing began in the 1990s with research by Lefebvre, who identified related deletions. PCR advancements by Roche improved detection, surpassing earlier Southern blot methods.
Purpose: Detects SMN1 exon 8 deletion status to diagnose spinal muscular atrophy, guides gene therapy or supportive care, and evaluates patients with muscle weakness, aiming to manage disease.
Test Parameters: SMN1 exon 8 deletion status
Pretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of muscle issues.
Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document muscle weakness. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., respiratory failure), and sample collection risks.
Procedural Considerations: Uses PCR to detect deletions, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Positive deletion confirms spinal muscular atrophy, guiding therapy. Early treatment might improve survival, while untreated cases lead to death. Normal results may require other tests.
Specialist Consultation: Consult a neurologist or genetic counselor for interpretation.
Additional Supporting Tests: Electromyography, muscle biopsy, or SMN1 exon 7 test to confirm diagnosis.
Test Limitations: Specific to exon 8; correlation with clinical status needed. False negatives possible with other mutations.
References: MDA Guidelines, 2023; Cell, Lefebvre S, 2022.
